PTN News and Press, Palatin Technologies Inc. From 05/14/25

Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update PR Newswire Significant Progress in Obesity and Ocular Programs Teleconference and Webcast to be held today - May 14, 2025 , at 11:00 AM EST CRANBURY, N.J. , May 14...

Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025 PR Newswire Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection P...

Palatin Technologies Announces Closing of Reduced Public Offering PR Newswire Company Transitioned onto the OTC Pink CRANBURY, N.J. , May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical...

Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025 PR Newswire Updated Phase 3 analysis highlights PL9643 as a potential first-in-class treatment achieving full symptom resolution. Re...

2025-05-08 15:00:50 ET Myomo Slides 29% Despite Record Revenue and Pipeline Growth Myomo Inc. (NYSE: MYO ) dropped 29.34%, leading the PRISM Emerging MedDevices Index , following the release of its Q1 2025 financial results . The company reported a 162% year-over-year in...

Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice PR Newswire The Company Intends to Request a Review of the Delisting Determination CRANBURY, N.J. , May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. ("Pal...

2025-05-07 08:56:47 ET More on Palatin Technologies Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript Palatin Technologies shares fall as it receives NYSE American delisting notice Palatin reported promising results in trial for ulcerative colitis tre...

Palatin Expects $11.5 Million Financing to Cure NYSE American Delisting Notice PR Newswire Funding Supports Advancement of Obesity Program and Strategic Business Development Initiatives Advancement of novel next-generation MC4R long-acting peptides and oral small mo...

Palatin Technologies Announces Pricing of up to $23 Million Public Offering PR Newswire $11.5 Million Upfront with up to an Additional $11.5 Million Upon the Cash Exercise of the Milestone Related Warrants CRANBURY, N.J. , May 7, 2025 /PRNewsw...

Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy PR Newswire Topical melanocortin therapy shows promise for treating glaucoma PL9588 lowers intraocular pressure (IOP) by increasing a...